Project Grant R43DK141319
Award Date
5/23/25
Completion Date
4/30/26
Dollars Obligated
$307K
Awardee
Geminii Inc. (C6AKMK29RNC6)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Iowa, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a novel Diabetes Targeted Dual Neuromodulation (TDN) therapy. The $345,650 grant will fund a Phase I feasibility study by Reshape Lifesciences Inc., a small business joint venture, to validate the hypothesis that decreasing the amplitude of the high frequency...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Visionquest Biomedical Inc. a $1,136,156 Project Grant under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program. The funding will support the development of an integrated smartphone-based system and educational materials to improve access to diabetic peripheral neuropathy (DPN) screening for underserved communities. Key objectives include identifying a portable thermal imaging...
This $310,897 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a first-in-class, islet-targeted antibody therapeutic for Type 1 Diabetes (T1D). The award supports preclinical development and validation activities for this novel antibody therapy, including establishing proof-of-principle for its islet-homing capability, therapeutic...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is supporting the development of novel therapeutics for obesity and type 2 diabetes. The $1,021,719 grant, awarded to Emmyon, Inc., will fund preclinical studies to advance the development of a proprietary small molecule compound (EMMY1-25) that promotes weight loss without muscle loss and...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $990,990 project grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Integrated Medical Sensors Inc., a minority-owned small disadvantaged business located in Irvine, CA. The project aims to optimize the manufacturing and quality framework for the company's miniaturized, integrated continuous glucose monitoring (CGM+) platform in preparation for larger human...
This $335,410 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a needle-free microneedle array patch (MAP) for delivering a GLP-1 receptor agonist to treat type 2 diabetes. The grant recipient, Vaxess Technologies, Inc., is a biotechnology company specializing in innovative MAP technologies for drug and vaccine...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,145,486 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Makscientific LLC, a for-profit research and development company located in Burlington, MA. The grant supports the development of novel peripherally acting CB1 neutral antagonists for treating diabetic kidney disease (DKD). The project aims to design and synthesize improved analogs of...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...